

Scheme S1. Schematic representation of the dynamics of the decrease in the intensity of the peaks of methyl groups after the addition of CD₃OD/CD₃ONa to 6-acetyl-7-methyl-1,2,4-triazolo[1,5-*a*]pyrimidine (**5**) in a time interval of 0-110 minutes at a temperature of (-10°C).




Figure S1. NOESY spectrum of 6-acetyl-7-methyl-1,2,4-triazolo [1,5-*a*]pyrimidine **5**.




Figure S2. 6-Acetyl-7-methyl-1,2,4-triazolo[1,5-*a*]pyrimidine **5**, T = 30°C.




Figure S3. 6-d₃-Acetyl-7-d₃-methyl-1,2,4-triazolo[1,5-*a*]pyrimidine **6**, T = 30°C.




Figure S4. 6-Acetyl-7-methyl-1,2,4-triazolo[1,5-*a*]pyrimidine 5, T = -10°C.




Figure S5. 6-d₃-Acetyl-7-d₃-methyl-1,2,4-triazolo[1,5-*a*]pyrimidine 6, *T* = -10°C after 5 min.




Figure S6. 6-d₃-Acetyl-7-d₃-methyl-1,2,4-triazolo[1,5-*a*]pyrimidine **6**, $T = -10^\circ\text{C}$ after 20 min.




Figure S7. 6-d₃-Acetyl-7-d₃-methyl-1,2,4-triazolo[1,5-*a*]pyrimidine **6**, $T = -10^\circ\text{C}$ after 40 min.





Figure S8. 6-d₃-Acetyl-7-d₃-methyl-1,2,4-triazolo[1,5-*a*]pyrimidine **6**, $T = -10^\circ\text{C}$ after 70 min.

Table S1. Kinetic study of the deuterium exchange from compound **5** to 6-d₃-acetyl-7-d₃-methyl-1,2,4-triazolo[1,5-*a*]pyrimidine **6** in CD₃OD + CD₃ONa at $T = -10^\circ\text{C}$.

Time (min)	¹ H-NMR (300 MHz, δ , ppm):
5	2.78 (s, 3.02H); 3.18 (s, 2.86H); 8.62 (s, 1H); 9.25 (s, 1H)
20	2.78 (s, 2.97H); 3.18 (s, 2.07H); 8.62 (s, 1H); 9.25 (s, 1H)
40	2.78 (s, 3.01H); 3.18 (s, 1.52H); 8.62 (s, 1H); 9.25 (s, 1H)
70	2.78 (s, 2.57H); 3.18 (s, 0.76H); 8.62 (s, 1H); 9.25 (s, 1H)



Scheme S2. Schematic representation of the dynamics of the decrease in the intensity of the peaks of methyl groups after the addition of $\text{CD}_3\text{OD}/\text{CD}_3\text{ONa}$ to 2,7-dimethyl-6-acetylpyrazolo[1,5-*a*]pyrimidine (**1**) in a time interval of 0-12 minutes at a temperature of (-15°C).




Figure S9. NOESY spectrum of 2,7-dimethyl-6-acetylpyrazolo[1,5-*a*]pyrimidine **1**.




Figure S10. 6-Acetyl-2,7-dimethylpyrazolo[1,5-*a*]pyrimidine **1**, T = 30°C.




Figure S11. 6-d3-Acetyl-7-d3-methyl-2-methylpyrazolo[1,5-*a*]pyrimidine **3**, T = 30°C.




Figure S12. 6-Acetyl-2,7-dimethylpyrazolo[1,5-*a*]pyrimidine **1**, T = -15°C.




Figure S13. 6-d₃-Acetyl-7-d₃-methyl-2-methylpyrazolo[1,5-*a*]pyrimidine **3**, $T = -15^{\circ}\text{C}$ after 2 min.




Figure S14. 6-d₃-Acetyl-7-d₃-methyl-2-methylpyrazolo[1,5-*a*]pyrimidine **3**, $T = -15^{\circ}\text{C}$ after 4 min.




Figure S15. 6-d₃-Acetyl-7-d₃-methyl-2-methylpyrazolo[1,5-*a*]pyrimidine **3**, $T = -15^{\circ}\text{C}$ after 6 min.




Figure S16. 6-d₃-Acetyl-7-d₃-methyl-2-methylpyrazolo[1,5-*a*]pyrimidine **3**, $T = -15^{\circ}\text{C}$ after 8 min.




Figure S17. 6-d₃-Acetyl-7-d₃-methyl-2-methylpyrazolo[1,5-*a*]pyrimidine **3**, $T = -15^{\circ}\text{C}$ after 10 min.





Figure S18. 6-d₃-Acetyl-7-d₃-methyl-2-methylpyrazolo[1,5-*a*]pyrimidine **3**, $T = -15^{\circ}\text{C}$ after 12 min.

Table S2. Kinetic study of the deuterium exchange from compound **1** to 6-d₃-acetyl-7-d₃-methyl-2-methylpyrazolo[1,5-*a*]pyrimidine **3** in CD₃OD + CD₃ONa at T = -15°C.

Time (min)	¹ H-NMR (300 MHz, δ, ppm):
2	2.50 (s, 3H); 2.65 (s, 2.23H); 3.14 (s, 1.83H); 6.55 (s, 1H); 8.82 (s, 1H)
4	2.50 (s, 3H); 2.65 (s, 1.59H); 3.14 (s, 1.1H); 6.55 (s, 1H); 8.82 (s, 1H)
6	2.50 (s, 3H); 2.65 (s, 1.52H); 3.14 (s, 0.78H); 6.55 (s, 1H); 8.82 (s, 1H)
8	2.50 (s, 3H); 2.65 (s, 1.18H); 3.14 (s, 0.39H); 6.55 (s, 1H); 8.82 (s, 1H)
10	2.50 (s, 3H); 2.65 (s, 0.45H); 3.14 (s, 0.042H); 6.55 (s, 1H); 8.82 (s, 1H)
12	2.50 (s, 3H); 2.65 (s, 0.77H); 3.14 (s, 0.0H); 6.55 (s, 1H); 8.82 (s, 1H)



Scheme S3. Schematic representation of the dynamics of the decrease in the intensity of the peaks of methyl groups after the addition of CD₃OD/CD₃ONa to 2,7-dimethyl-5-ethoxycarbonylpyrazolo[1,5-*a*]pyrimidine (**10**) in a time interval of 0-70 minutes at a temperature of (-10°C).




Figure S20. 2,7-Dimethyl-5-ethoxycarbonylpyrazolo[1,5-*a*]pyrimidine **10**, T = 30°C.




Figure S21. 2,7-Dimethyl-5-ethoxycarbonylpyrazolo[1,5-*a*]pyrimidine **10**, T = 30°C.




Figure S22. 7-d3-Methyl-2-methyl-5-d3-methoxycarbonylpyrazolo[1,5-a]pyrimidine **10**, T = 30°C.




Figure S23. 2,7-Dimethyl-5-ethoxycarbonylpyrazolo[1,5-a]pyrimidine **10**, T = -10°C.




Figure S24. 7-d3-Methyl-2-methyl-5-d3-methoxycarbonylpyrazolo[1,5-a]pyrimidine **14**, T = -10°C after 10 min.




Figure S25. 7-d₃-Methyl-2-methyl-5-d₃-methoxycarbonylpyrazolo[1,5-*a*]pyrimidine **14**, T = -10°C after 30 min.




Figure S26. 7-d₃-Methyl-2-methyl-5-d₃-methoxycarbonylpyrazolo[1,5-*a*]pyrimidine **14**, T = -10°C after 45 min.




Figure S27. 7-d₃-Methyl-2-methyl-5-d₃-methoxycarbonylpyrazolo[1,5-*a*]pyrimidine **14**, T = -10°C after 70 min.

Table S3. Kinetic study of the deuterium exchange from compound **10** to 7-d₃-methyl-2-methyl-5-d₃-methoxycarbonylpyra-zolo[1,5-*a*]pyrimidine **14** in CD₃OD + CD₃ONa at T = -10°C.

Time (min)	¹ H-NMR (300 MHz, δ, ppm):
5	1.2 (t, 3H); 2.55 (s, 3H); 3.6 (q, 2H); 6.7 (s, 1H); 7.45 (s, 1H)
10	1.42(t, 3H); 2.55 (s, 3H); 2.82 (s, 2.83H); 4.45 (q, 2H); 6.7 (s, 1H); 7.45 (s, 1H)
30	1.42(t, 3H); 2.55 (s, 3H); 2.82 (s, 2.35H); 4.45 (q, 2H); 6.7 (s, 1H); 7.45 (s, 1H)
45	1.42(t, 3H); 2.55 (s, 3H); 2.82 (s, 2.26H); 4.45 (q, 2H); 6.7 (s, 1H); 7.45 (s, 1H)
70	1.42(t, 3H); 2.55 (s, 3H); 2.82 (s, 1.98H); 4.45 (q, 2H); 6.7 (s, 1H); 7.45 (s, 1H)